Can a patient start Mavyret (glecaprevir + pibrentasvir) and discontinue it if it is not tolerated?

Can Mavyret Be Discontinued If Not Tolerated?

Yes, Mavyret (glecaprevir/pibrentasvir) can be discontinued if not tolerated, though this is rarely necessary given its excellent safety profile. However, discontinuation should be approached cautiously as incomplete treatment courses may lead to treatment failure and potential development of resistance.

Safety Profile and Tolerability

Mavyret demonstrates exceptional tolerability across multiple populations. The most common adverse events are mild and include:

• Headache (8-9%)
• Fatigue (9-11%)
• Pruritus (8-11%)
• Nausea (6%)
• Abdominal pain (14% in pediatric populations) 1, 2, 3, 4, 5, 6

Serious adverse events are rare (2-3.5%), and none are typically treatment-related 2, 4, 5. Across extensive clinical trial and real-world data involving thousands of patients, treatment discontinuation due to adverse events is extraordinarily uncommon—occurring in less than 0.3-1% of patients 2, 4, 5, 7.

When Discontinuation May Be Necessary

Absolute Contraindications Requiring Immediate Discontinuation:

The FDA label specifies that Mavyret must be discontinued if patients develop:

• Decompensated cirrhosis (Child-Pugh B or C) during treatment 8
• Severe hepatic impairment that develops on treatment
• Concurrent use with contraindicated medications including:
  • Atazanavir (increased ALT elevation risk)
  • Rifampin (loss of therapeutic effect) 8

Situations Requiring Dose Modification of Concomitant Medications (Not Mavyret Discontinuation):

Rather than stopping Mavyret, the FDA label emphasizes managing concomitant medication interactions 8:

• Symptomatic hypoglycemia in diabetic patients: Adjust diabetes medications, not Mavyret
• Subtherapeutic INR in warfarin users: Monitor and adjust warfarin dosing
• Drug interactions with narrow therapeutic index medications: Adjust the interacting drug

Clinical Approach to Tolerability Concerns

Step 1: Assess the Severity

• Mild symptoms (headache, fatigue, nausea): Provide symptomatic management and reassurance; these typically resolve without intervention
• Laboratory abnormalities: Monitor closely but recognize that ALT elevations often improve during treatment rather than worsen 2

Step 2: Rule Out Alternative Causes

• Ensure symptoms aren't related to concomitant medications or underlying conditions
• Check for drug-drug interactions that may be causing symptoms 8

Step 3: Consider Treatment Duration

• 8-week regimens (treatment-naïve without cirrhosis): Shorter duration may improve adherence 1, 5
• 12-week regimens (treatment-experienced with cirrhosis): Balance completion against tolerability
• Patients are often near completion when symptoms arise, making continuation preferable

Step 4: Weigh Risks of Discontinuation

• Incomplete treatment leads to virologic failure and potential resistance
• SVR12 rates exceed 97-99% with complete treatment across all populations 2, 3, 4, 5, 7
• Retreatment options exist but add complexity and cost

Real-World Evidence

Multiple real-world studies demonstrate that no patients discontinued Mavyret due to adverse events in cohorts of cirrhotic patients 3, 4. Even in vulnerable populations including:

• Recent/current injection drug users (14.3%)
• HIV coinfected patients (49.7%)
• Pediatric patients (ages 3-17)
• Pregnant women 2, 9, 6

The treatment was completed successfully with minimal safety concerns.

Key Pitfalls to Avoid

1. Don't discontinue prematurely for mild, self-limiting symptoms that don't compromise safety
2. Don't confuse drug interactions requiring concomitant medication adjustment with need to stop Mavyret
3. Don't overlook that hepatic function often improves during HCV treatment, so baseline ALT elevations typically decrease rather than worsen 2
4. Don't forget that loss to follow-up is more common than true intolerance—in real-world data, 19 patients were lost to follow-up versus only 1 discontinuation for adverse events 3

Bottom Line

While Mavyret can technically be discontinued if not tolerated, true intolerance requiring discontinuation is exceptionally rare (< 0.3%). Most adverse events are mild, self-limiting, and manageable with supportive care or adjustment of concomitant medications rather than stopping Mavyret itself 8, 2, 3, 4, 5. The decision to discontinue should only be made after careful assessment of symptom severity, exclusion of alternative causes, and consideration of the high likelihood of achieving cure with treatment completion.